Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥ 18 years of age
- • diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated
- • Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation.
- • read and signed the Informed Consent Form
- Exclusion Criteria:
- • Any contraindications as per approved SmPC of Brilique
- • • Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belgrade, , Serbia
Kragujevac, , Serbia
Kragujevac, , Serbia
Nis, , Serbia
Belgrade, , Serbia
Belgrade, , Serbia
Belgrade, , Serbia
Belgrade, , Serbia
Belgrade, , Serbia
Sremska Kamenica, , Serbia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials